Quadrature Capital Ltd Buys Shares of 17,946 Veradigm Inc. (NASDAQ:MDRX)

Quadrature Capital Ltd bought a new stake in Veradigm Inc. (NASDAQ:MDRX – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,946 shares of the software maker’s stock, valued at approximately $273,000.

Several other large investors also recently bought and sold shares of MDRX. Point72 Asset Management L.P. acquired a new stake in Veradigm in the second quarter valued at $18,578,000. Creative Planning grew its holdings in Veradigm by 974.5% in the third quarter. Creative Planning now owns 1,286,015 shares of the software maker’s stock valued at $19,586,000 after purchasing an additional 1,166,330 shares during the last quarter. Millennium Management LLC grew its holdings in Veradigm by 72.7% in the second quarter. Millennium Management LLC now owns 2,480,364 shares of the software maker’s stock valued at $36,784,000 after purchasing an additional 1,044,236 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Veradigm in the second quarter valued at $12,807,000. Finally, Citadel Advisors LLC grew its holdings in Veradigm by 125.2% in the third quarter. Citadel Advisors LLC now owns 1,480,863 shares of the software maker’s stock valued at $22,553,000 after purchasing an additional 823,345 shares during the last quarter. Institutional investors and hedge funds own 99.76% of the company’s stock.

Veradigm Stock Down 2.2 %

Shares of NASDAQ:MDRX opened at $13.58 on Tuesday. The stock’s 50-day moving average price is $17.14 and its two-hundred day moving average price is $16.88. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.17. Veradigm Inc. has a 12-month low of $13.51 and a 12-month high of $23.25. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of 31.58, a PEG ratio of 1.28 and a beta of 1.01.

Analysts Set New Price Targets

A number of analysts recently commented on MDRX shares. SVB Securities decreased their price objective on Veradigm from $24.00 to $17.00 in a research note on Wednesday, March 1st. JPMorgan Chase & Co. increased their price objective on Veradigm from $19.00 to $20.00 and gave the company an “underweight” rating in a research note on Friday, November 18th. Argus raised Veradigm from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Wednesday, December 7th. They noted that the move was a valuation call. Piper Sandler lowered Veradigm from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $17.00 to $18.50 in a research note on Wednesday, February 1st. Finally, TheStreet raised Veradigm from a “c+” rating to a “b-” rating in a research note on Wednesday, November 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, Veradigm presently has an average rating of “Hold” and an average target price of $20.90.

Veradigm Profile

(Get Rating)

Veradigm, Inc engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units.